Better be _老虎社区_美港股上老虎

66f35aa5
2021-10-04

Better be cautious

Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials

Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021

Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":820077600,"tweetId":"820077600","gmtCreate":1633334091941,"gmtModify":1633334092226,"author":{"id":3585027190392565,"idStr":"3585027190392565","authorId":3585027190392565,"authorIdStr":"3585027190392565","name":"66f35aa5","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Better be cautious</p></body></html>","htmlText":"<html><head></head><body><p>Better be cautious</p></body></html>","text":"Better be cautious","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/820077600","repostId":2172998129,"repostType":4,"repost":{"id":"2172998129","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1633332318,"share":"https://www.laohu8.com/m/news/2172998129?lang=&edition=full","pubTime":"2021-10-04 15:25","market":"us","language":"en","title":"Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2172998129","media":"T-Reuters","summary":"Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021","content":"<p>Merck KGaA:&nbsp;Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk). </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-10-04 15:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck KGaA:&nbsp;Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk). </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172998129","content_text":"Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk).","news_type":1},"isVote":1,"tweetType":1,"viewCount":586,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials

评论（1）

热议股票